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Ltd. This is an open access article unAbstract Objective: To investigate the expression of p16, cyclin D1, retinoblastoma tumor
suppressor protein (Rb) and MIB-1 in skull base chordoma and chondrosarcoma tissues, and
to determine the clinicopathological significance of the above indexes in these diseases.
Methods: A total of 100 skull base chordoma, 30 chondrosarcoma, and 20 normal cartilage tis-
sue samples were analyzed by immunohistochemistry. The expression levels of p16, cyclinD1,
Rb and MIB-1 proteins were assessed for potential correlation with the clinicopathological fea-
tures.
Results: As compared to normal cartilage specimen (control), there was decreased expres-
sion of p16, and increased expression of cyclin D1, Rb and MIB-1 proteins, in both skull base
chordoma and chondrosarcoma specimens. MIB-1 LI levels were significantly increased in
skull base chordoma specimens with negative expression of p16, and positive expression of
cyclin D1 and Rb (P < 0.05). Significantly elevated MIB-1 LI was also detected in skull base
chondrosarcoma tissues, while there was negative expression of p16, cyclin D1 and Rb
(P < 0.05). In skull base chordoma, p16 negatively correlated with cyclin D1 and Rb, while
cyclin D1 positively correlated with Rb. Additionally, p16, cyclin D1, Rb, or MIB-1 expression
showed no correlation with age, gender, or pathological classification of patients with skull
base chordoma (P > 0.05). However, p16 and MIB-1 levels correlated with the intradural in-
vasion, and expression of p16, Rb and MIB-1 correlated with the number of tumor foci
(P < 0.05). Further, the expression of p16 and MIB-1 appeared to correlate with the prognosis
of patients with skull base chordoma.t of Otolaryngology, Head & Neck Surgery, Xuanwu Hospital Capital Medical University, No.45
Beijing 100053, China. Tel./fax: þ86 83198446.
.com (Q.-h. Zhang).
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(CD), and chondrosarcoma (CH
negatively express p16/cyclin D1/
CD
MIB-1 LI P valu
p16
Negative 10.6 0.015
Positive 4.2
Cyclin D1
Negative 3.9 0.015
Positive 9.4
Rb
Negative 5.4 0.025
Positive 8.6
*MIB-1 LI is the positive rate of imm
with anti-MIB-1.Conclusions: The abnormal expression of p16, cyclin D1 and Rb proteins might be associated
with the tumorigenesis of skull base chordoma and chondrosarcoma.
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Skull base chordoma and chondrosarcoma are unusual
central skull base tumors which differ in origin, histopa-
thology, and therapeutic outcomes.1,2 Chordoma, a low-
grade malignancy, is a midline primary tumor arising from
the ectopic remnants of embryonal notochord,3,4 while
chondrosarcoma is of mesodermal origin.5,6 Chordoma and
chondrosarcoma of the skull base are both invasive tumors,
with similar clinical symptoms, anatomic location, as well
as radiological findings.1 The prognosis of these diseases
largely depends on the treatment strategy such as, extent
of surgical resection and adjuvant radiotherapy.7
Some studies have examined the molecular basis of
carcinogenesis by investigating the types and status of
proteins that are linked with prognosis in patients with
chordoma.3 For instance, MIB-1 (or Ki-67) labeling index
(LI), which is related to tumor cell proliferation, was shown
to correlate with the doubling time of skull base chordoma
lesions.8 Low MIB-1 value is thought to predict the low-
grade propensity of most chordomas.9 MIB-1, cyclin D1
and p53 were identified as important biomarkers for pre-
dicting recurrence in chordomas.10 In addition, biomarkers
that can distinguish skull base chordoma from chon-
drosarcoma have also been identified. CD24 and brachyury
are known to be solely expressed in chordoma,11 while
podoplanin is known to be selectively expressed in chon-
drosarcoma.12 However, the accuracy and sensitivity of
these biomarkers still needs to be determined.
The retinoblastoma (Rb) pathway, consisting of p16-
cyclin D1edependent kinases 4/6 (CDK4/6)-Rb proteins,
plays a pivotal role in regulating cell proliferation by
modulating the transition of G1/S phase of the cell cycle.13s in skull base chordoma
S) tissues positively or
Rb.
CHS
e MIB-1 LI P value
7.4 0.008
2.2
3.1 0.025
2.2
4.3 0.018
2.7
unohistochemistry stainingMutations of this pathway have been detected in different
types of malignancies in humans.14 Nevertheless, evidence
supporting the involvement of Rb pathway in tumorigenesis
of skull base chordoma or chondrosarcoma, is rather
limited.
In order to understand the clinicopathological signifi-
cance of the critical proteins in Rb pathway, we assessed
the expression of p16, cyclin D1, Rb proteins in tissue
specimens of chordoma, chondrosarcoma and normal
cartilage tissues. Profiling the respective molecular differ-
ences may provide valuable insights into the molecular
mechanisms underlying carcinogenesis, and may facilitate
the differential diagnosis and patient management.15 Our
results highlight the crucial role of Rb signal pathway in the
development and progression of skull base tumors.
Materials and methods
Sample collection
We collected samples from patients undergoing surgical
resection of skull base chordoma (n Z 100) and chon-
drosarcoma (n Z 30), at Xuanwu Hospital Capital Medical
University, Beijing, China between July 2005 and December
2012. The average age of these patients was 40 years.
Among the 100 cases of skull base chordoma, 55 were male
and 45 were female. The demographic and clinicopatho-
logical characteristics of patients are listed in Table 1. Skull
base chordoma was identified by pathological examination.
Among 100 cases of skull base chordoma, 79 were identified
as standard chordoma, and 18 cases were identified as
cartilaginous chordoma according to pathological
morphology and the immunohistochemical staining of
tumor cells. Similarly, 30 samples of chondrosarcoma,
included 21 cases of chondrosarcoma NOS (“Not Otherwise
Specified”), 5 cases of myxoid chondrosarcoma, and 4 cases
of mesenchymal chondrosarcoma. Twenty normal cartilage
tissue specimens obtained from Department of Pathology
served as controls for the purpose of this study. Ethical
approval for this study was granted by Xuanwu Hospital
Capital Medical University, Beijing, China.
Reagents
Primary antibodies, including mouse anti-human anti-p16
antibody, anti-cyclin D1 antibody, anti-Rb antibody, anti-
MIB-1 antibody, and 3, 30-diaminobenzidine tetrahydro-
chloride (DAB) kit were purchased from Maxin Biotech Inc.,
Fuzhou, China. Other chemicals and reagents were ob-
tained from Beijing Chemical Reagent Company, China,
unless stated otherwise.
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Paraffin-embedded tissue samples were sectioned using an
automatic tissue processor (S325, Shandon, UK). Four
micrometer-thick sections were deparaffinized in xylene
and rehydrated in an ethanol series (100% for 5 min, 95% for
5 min, 95% for 5 min, and distilled water). Following this,
samples were washed with phosphate buffered saline (PBS)
and incubated with 3% hydrogen peroxide for 15 min at RT.
Sections were heated in citrate buffer (0.1 mmol/L, pH 6.0)
for 15 min at 92Ce98 C. After blocking with normal goat
serum, samples were incubated with primary antibody at
appropriate dilution (anti-p16, 1:80; anti-cyclin D1, 1:40;
anti-Rb, 1:100; anti-MIB-1, 1:80) for 60 min at 37 C fol-
lowed by overnight incubation at 4 C. After washing with
PBS, sections were probed with secondary antibody using
MaxVision HRP-Polymer anti-Mouse/Rabbit IHC kit ac-
cording to manufacturer’s instructions (Maxin Biotech Inc.,
Fuzhou, China). Immunostaining was visualized by DAB. The
nuclei were counterstained with hematoxylin solution.
Samples were then dehydrated through ethanol series,
cleared in xylene, and mounted. Negative control samples
were incubated with PBS instead of primary antibody. Some
sections were stained with hematoxylin and eosin (HE) for
histological examination.
Imaging analysis
Images were captured using optical microscope (BX51,
Olympus, Japan) at 400 magnification. A total of 100 cells
were randomly selected from each visual field and data
were quantified from five fields. Cells with yellow/brown
stain in cytosol (e.g. p16, Rb) or in the nucleus (e.g. cyclin
D1, Rb, MIB-1) were considered as positive cells.
To semi-quantify the MIB-1 staining, cells with yellow
brown or dark brown staining in nuclei were identified as
MIB-1-positive cells. The percentage of MIB-1-positive cells
in each visual field (magnification 400) was calculated.
The average number of cells was calculated from five non-
overlapping fields. MIB-1 labeling index (LI) was calculated
using the equation: LI Z (Number of MIB-1-positive cells/
Total number of cells)  100.
Follow up study of patients with skull base
chordoma
Among 100 cases with skull base chordoma, 72 patients
received total removal of tumor mass in our hospital,62.50%
of which (45 cases)were initially diagnosed as chordoma,
and 28 patients received subtotal resection, 17.85% of
which (5 cases)were initially diagnosed as chordoma. They
were followed for 3 months to 10 years. The average time
for follow up study was 23 months.
Statistical analysis
Data were analyzed using SPSS 17.0 software (IBM SPSS).
Categorical variables were compared with Wilcoxon rank
sum test. The correlation between the protein expression
levels was analyzed using chi square test, and thecorrelation coefficient r was determined. P < 0.05 was
considered statistically significant.
Results
Expression of p16, cyclin D1, Rb and MIB-1 proteins
in skull base chordoma, chondrosarcoma and
normal cartilage tissues
The cancer samples of chordoma, chondrosarcoma and
normal cartilage tissues were subjected to IHC staining using
specific antibody against p16, cyclin D1, Rb and MIB-1 pro-
teins. As shown in Fig. 1, p16 was mainly located in cytosol;
cyclin D1 and MIB-1 weremainly expressed in nuclei; while Rb
was detected in both cytosol and nuclei. Compared to the
normal cartilage control, the positive expression of p16
decreased in skull base chordoma and chondrosarcoma tis-
sues. In addition, significant differences were found between
the two types of sarcomas with respect to expression of p16,
cyclin D1, Rb and MIB-1 (P < 0.05 for all indexes) in compar-
isonwith thecontrol tissues. Besides, among100casesof skull
base chordoma, 79 cases were identified as standard chor-
doma, and 18 cases were identified as cartilaginous chor-
doma. There was no significant difference in expression of
these 4 proteins between standard and cartilaginous chor-
doma. (P > 0.05 for all indexes) (Table 2).
Correlation between MIB-1 and p16/cyclin D1/Rb in
skull base chordoma and chondrosarcoma
We further investigated the correlation between expression
of MIB-1 and p16/cyclin D1/Rb proteins in chordoma and
chondrosarcoma samples. For this purpose, the average
MIB-1 LI value was determined in both types of sarcomas,
and was further correlated with positive or negative
expression status of p16, cyclin D1, and Rb. The average
MIB-1 LI level was higher in skull base chordoma tissues
than in chondrosarcoma (Table 1). MIB-1 LI value was
significantly increased in skull base chordoma tissues and
correlated with negative expression of p16, and with posi-
tive expression of cyclin D1 and Rb (P < 0.05). Additionally,
a significantly elevated MIB-1 LI expression was also noted
in chondrosarcoma tissues with negative expression of p16,
cyclin D1 and Rb (P < 0.05). Spearman correlation analysis
revealed that in the skull base chordoma samples, p16
negatively correlated with cyclin D1 and Rb (p16 vs. cyclin
D1, P < 0.01, correlation coefficient r Z 0.514; p16 vs.
Rb, P < 0.01, r Z 0.403), while cyclin D1 positively
correlated with Rb (P < 0.01, r Z 0.677) (Table 3). Among
30 cases of chondrosarcoma, the MIB-1 LI value for 70% of
chondrosarcoma NOS 16.7% of myxoid chondrosarcoma and
13.3% of mesenchymal chondrosarcoma was 2.1, 3.1, and
7.4, respectively (P < 0.05).
Association between p16/cyclin D1/Rb/MIB-1 and
the demographic and clinical characteristics of
patients with skull base chordoma
We investigated potential association of expression levels
of p16/cyclin D1/Rb/MIB-1 with the demographic and
Fig. 1 Histopathological and immunohistochemical study of skull base chordoma and chondrosarcoma specimens. A) HE stained
tissue sections; B) Tissue sections immunostained with specific antibodies against p16, cyclin D1, Rb and MIB-1 proteins. Nuclei are
counterstained with hematoxylin. Scale bar, 50 mm; (C) Positive expression rate of p16, cyclin D1, Rb and MIB-1 proteins by study
group.
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Table 4, the expression of p16, cyclin D1, Rb, or MIB-1 was
not associated with age, gender, or pathological features of
the patients with skull base chordoma (P > 0.05 for all in-
dexes). Although expression of cyclin D1 and Rb did notTable 2 Expression levels of p16/cyclin D1/Rb/MIB-1 be-
tween standard and cartilaginous chordoma. Data are pre-
sented in terms of frequencies.
Standard CH Cartilaginous CH P value
Positive rate Positive rate
p16 9/79 5/18 >0.05
cyclin D1 40/79 9/18 >0.05
Rb 44/79 10/18 >0.05
MIB-1 10/79 3/18 >0.05
*Positive Rate is the percentage of positive sections with
immunohistochemistry staining.correlate, the expression of p16 and MIB-1 appeared to
correlate with intradural invasion (P < 0.05), while no such
association was found for cyclin D1 and Rb proteins
(P > 0.05). Moreover, the expression of p16, Rb and MIB-1,
but not cyclin D1, was related to the number of tumor foci
(P < 0.05).Follow up of patients with skull base chordoma
Among 24 cases with skull base chordoma, 15 cases (Group
A) had disease recurrence 2 years after surgical treatment,
with an average recurrence time of 7 months, while 9 cases
(Group B) were disease free. There was negative expres-
sion of p16 in 8 cases (53.3%) of Group A), while it was
absent only in 2 cases (22.2%) of Group B. Moreover,
expression of MIB-1 was detected in 13 cases of Group A
(86.7%), while it was found in only 3 cases in Group B
(33.3%). These findings suggest that the expression of p16
and MIB-1 might be related to prognosis in patients with
skull base chordoma.
Table 4 Association between expression levels of p16/cyclin D1/Rb/MIB-1 and the demographic and clinical characteristics of
patients with skull base chordoma. Data are presented in terms of frequencies.
n p16 Cyclin D1 Rb MIB-1
Negative Positive P
value
Negative Positive P
value
Negative Positive P
value
Negative Positive P
value
Age (yr)
<40 47 41 6 >0.05 32 15 >0.05 29 17 >0.05 32 15 >0.05
40 53 44 9 36 17 32 21 34 19
Gender
Male 55 46 9 >0.05 38 17 >0.05 35 20 >0.05 30 25 >0.05
Female 45 39 6 30 15 26 19 36 9
Intradural invasion
Yes 28 24 4 <0.05 14 14 >0.05 17 11 >0.05 4 24 <0.05
No 55 21 34 30 25 29 26 40 15
Number of tumor foci
Single 37 20 17 <0.05 17 20 >0.05 13 15 <0.05 12 25 <0.05
2 50 37 13 22 28 39 11 31 19
Pathological type
Standard
chordoma
79 70 9 >0.05 20 59 >0.05 15 64 >0.05 6 73 >0.05
Cartilaginous
chordoma
18 12 2 4 14 3 15 2 16
Table 3 Correlation of p16, cyclin D1 and Rb protein levels in skull base chordoma samples. Data are presented in terms of
frequencies.
p16 P value
r value
Rb P value
r valueNegative Positive Negative Positive
Cyclin D1
Negative 38 13 P < 0.01
r Z 0.514
39 12 P < 0.01
r Z 0.677
Positive 47 2 6 43
Rb
Negative 32 13 P < 0.01
r Z 0.403Positive 53 2
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In the present study, we investigated the expression of the
key mediators in the Rb signaling pathway in skull base
chordoma and chondrosarcoma specimens using immuno-
histochemical analysis. We observed an association of the
expression of p16, cyclin D1, Rb and MIB-1 proteins with the
clinicopathological parameters in skull base tumors.
Cell cycle is important for the duplication of cells and
growth of an organism, hence it is tightly regulated. It is
accepted that tumor cells may evolve partially by over-
riding the cell cycle regulation.16 Cyclin D1 is one of the
essential mediators in the regulation of cell cycle. Cyclin D1
binds to and induces the activation of CDK4 and CDK6,
which in turn results in phosphorylation of Rb, leading to
progression of cell cycle from G1 phase into S phase.17 In-
hibition of CDK, for example, by the tumor suppressor p16,
can prevent the G1 to S phase transition.18,19 Here, we
found that the positive expression of p16 decreased,whereas there was increased expression of cyclin D1, and
Rb in skull base chordoma and chondrosarcoma tissues,
when compared to that in normal cartilage controls. The
pathological findings implicate the derangement of multi-
ple components of the Rb signal pathway in the causation
and progression of skull base tumors.
p16 is a widely accepted tumor suppressor protein that
regulates cell cycle.20 The expression of p16 is reportedly
downregulated in several tumors, such as glioblastomas,
lymphomas, leukemia, liver, lung, bladder, and breast
cancers.20 Consistent with these findings, we too detected
reduced p16 expression in skull base chordoma and chon-
drosarcoma. Besides, we observed a close association be-
tween the expression of p16 and MIB-1 LI, since the MIB-1 LI
level was significantly increased in skull base chordoma and
chondrosarcoma samples that showed a concomitant loss of
p16 expression. The negative expression of p16 was asso-
ciated with the development of intradural invasion and an
increased number of tumor foci in patients with skull base
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loss with disease progression. However, the level of p16
showed no correlation with variables such as age, gender or
pathological classification of skull base chordoma. Since
increased MIB-1 LI value correlated with increasing histo-
logical grade of most chordoma samples,9 it appears to be a
potential risk factor for aggressive disease progression and
reduced survival time in these cancers.21 Some reports have
indicated a correlation between loss of p16 expression and
high-grade central chondrosarcoma.22 Further, p16 and
MIB-1 LI levels might be of value in predicting the histo-
logical grade and progression of skull base tumors. Further,
MIB-1 expression and loss of p16 expression was found to be
associated with tumor recurrence. Our findings indicate the
prognostic significance of p16 and MIB-1 in patients with
skull base tumors.
Cyclin D1 was found to be highly expressed in 49% of
skull base chordoma and 33% of chondrosarcoma samples,
compared to its low expression in 25% of normal cartilage
samples. Consistent with our findings, another study
claimed that 62% (17 out of 27) cases of high-grade chon-
drosarcoma express cyclin D1.23 The cyclin D1 expression
correlates with the high MIB-1 LI value and the recurrence
of chordomas.10 We did not detect any association between
cyclin D1 expression and the demographic or clinicopatho-
logical variables including age, gender, intradural invasion,
number of tumor foci, and tumor classification.
Positive expression of Rb was found in 55%, 40%, and 30%
of the chordoma, chondrosarcoma and control samples,
respectively. In addition, the level of Rb was found to be
closely associated with the number of tumor foci, which
suggested that the increased Rb expression might correlate
with enhanced tumor proliferation and invasion. These re-
sults are in accordance with previous report of the alter-
nation of Rb pathway in high-grade chondrosarcoma.23 We
speculate that the reduced p16 expression, and thereby
enhanced cyclin D1 and Rb activity, may contribute to
tumorigenesis of skull base tumors.
In summary, our current study demonstrates the clini-
copathological significance of the p16-cyclin D1-Rb
pathway and the MIB-1 level in skull base chordoma and
chondrosarcoma. We believe that therapies targeting the
cell cycle regulation, by exogenous over-expression of
p16,20,24 or introduction of the anti-sense oligonucleotides
of cyclin D1,25 or interference of Rb activity, may prove
valuable in the treatment of cancer.26 In addition, the
molecular mechanisms involved in the Rb pathway (CDK4/6
pathway) and tumorigenesis of skull base tumors are being
researched.27 Future studies should employ both in vitro
studies of cultured tumor cells, as well as animal disease
models to unravel the underlying mechanisms. The small
sample size is one of the limitations of our study. Future
studies involving larger sample sizes could provide more
definitive evidence and help substantiate the leads
emanating from this study. The association between the Rb
signal pathway regulators and disease prognosis is of
particular clinical import.Conflicts of interest
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